

CRITICAL THERAPEUTICS INC  
Form 425  
October 31, 2008

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **October 31, 2008**

**Critical Therapeutics, Inc.**  
(Exact Name of Registrant as Specified in Charter)

**Delaware**                                      **000-50767**                                      **04-3523569**  
(State or Other Jurisdiction                      (Commission                                      (IRS Employer  
of Incorporation)                                      File Number)                                      Identification  
No.)

**60 Westview Street, Lexington, Massachusetts 02421**  
(Address of Principal Executive Offices)                                      (Zip Code)  
Registrant's telephone number, including area code: **(781) 402-5700**

**Not applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**Item 8.01 Other Events.**

On October 31, 2008, Critical Therapeutics, Inc. (the "Company") issued a press release announcing that its stockholders, at the special meeting of stockholders held on the same date, voted to approve all of the matters related to the proposed merger with Cornerstone BioPharma Holdings, Inc. The press release also announced that the Company's board of directors has approved a 10-to-1 reverse stock split of the Company's common stock, which will be effective immediately prior to the closing of the proposed merger. The press release, which is attached as Exhibit 99.1 hereto, is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

See the Exhibit Index attached hereto.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 31, 2008 CRITICAL  
THERAPEUTICS, INC.

By: /s/ Thomas P. Kelly  
Thomas P. Kelly  
Chief Financial Officer  
and Senior

Vice President of  
Finance and

Corporate  
Development

---

**EXHIBIT INDEX**

**Exhibit No.   Description**

99.1            Press release dated October 31, 2008.